


LIVER CENTER SEMINAR

Wednesday, November 9, 2016
10:00-11:00 AM, S-214, Parnassus

Bernd Schnabl, MD

University of California San Diego

Are proton pump inhibitors safe for patients with chronic liver disease?



If you would like to meet with Dr. Schnabl after the lecture, please email Sandhya Adiyodi Veetil at Sandhya.AdiyodiVeetil@ucsf.edu

Dr. Schnabl is a physician-scientist who focuses on the pathogenesis of chronic liver disease. His laboratory pioneered work describing the intestinal microbiome associated with liver disease in preclinical models and patients. His lab is leading the research field in investigating functional consequences of dysbiosis for chronic liver diseases. His efforts lead to a proof of concept that precision microbiome approaches can prevent chronic liver disease.

Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates TNFRI and mediates alcoholic liver disease in mice. *Hepatology*. 2015; 61(3):883-94.

Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. *Gastroenterology*. 2015;148(1):203-214.

Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect Against Alcoholic Steatohepatitis by Reducing Mucosa-associated Microbiota and Preventing Bacterial Translocation. *Cell Host Microbe*. 2016; 19(2):227-239.

Arroyo V, Moreau R, Kamath PS, Jalan R, Gines P, Nevens F, Fernandez J, To U, Garcia-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. *Nature Reviews Disease Primers*. 2016; 2:16041.